source
- Nascent US psychedelic therapy opportunity attracts overseas manufacturersCompanies that manufacture MDMA and psilocybin for patients in other countries are looking to use their experience to access the potential U.S. market.BioSpace · 34m ago↗ source
- Taiho and Cullinan’s zipalertinib shows progression‑free survival benefit in Phase 3 NSCLC trialTaiho Pharmaceutical and Cullinan Therapeutics reported that their EGFR inhibitor zipalertinib, combined with chemotherapy, significantly extended progression‑free survival for patients with advanc…